These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35116273)

  • 1. Periostin is a novel histological biomarker for the diagnosis of chondroid tumor.
    Kim D; Jeong JY; Han MH; Chae J; Park I; Yoon J; Kyung H; Kim HJ; Jeong W
    Transl Cancer Res; 2021 Jan; 10(1):434-444. PubMed ID: 35116273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma.
    Lai X; Chen S
    Proteomics; 2015 Jul; 15(13):2358-68. PubMed ID: 25755173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chondroid Tumors as Incidental Findings and Differential Diagnosis between Enchondromas and Low-grade Chondrosarcomas.
    Afonso PD; Isaac A; Villagrán JM
    Semin Musculoskelet Radiol; 2019 Feb; 23(1):3-18. PubMed ID: 30699449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature.
    Subhawong TK; Winn A; Shemesh SS; Pretell-Mazzini J
    Skeletal Radiol; 2017 Sep; 46(9):1233-1239. PubMed ID: 28608242
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Annovazzi A; Anelli V; Zoccali C; Rumi N; Persichetti A; Novello M; Sciuto R; Bertoni F; Ferraresi V; Biagini R
    Ann Nucl Med; 2019 Nov; 33(11):813-821. PubMed ID: 31396797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
    Huse JT; Pasha TL; Zhang PJ
    Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
    Joseph NM; McGill KC; Horvai AE
    Am J Surg Pathol; 2021 Jun; 45(6):812-819. PubMed ID: 33239505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of MicroRNA biomarkers to distinguish enchondroma from low-grade chondrosarcoma.
    Zhang L; Yang M; Mayer T; Johnstone B; Les C; Frisch N; Parsons T; Mi QS; Gibson G
    Connect Tissue Res; 2017 Mar; 58(2):155-161. PubMed ID: 27267924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating clinical and radiographic features of enchondroma and secondary chondrosarcoma in the foot.
    Gajewski DA; Burnette JB; Murphey MD; Temple HT
    Foot Ankle Int; 2006 Apr; 27(4):240-4. PubMed ID: 16624212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of chondrosarcoma.
    Jeong W; Kim HJ
    J Clin Pathol; 2018 Jul; 71(7):579-583. PubMed ID: 29593061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
    Sangoi AR; Dulai MS; Beck AH; Brat DJ; Vogel H
    Am J Surg Pathol; 2009 May; 33(5):669-81. PubMed ID: 19194275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What are the differentiating clinical and MRI-features of enchondromas from low-grade chondrosarcomas?
    Douis H; Parry M; Vaiyapuri S; Davies AM
    Eur Radiol; 2018 Jan; 28(1):398-409. PubMed ID: 28695356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of insulin-like growth factor II mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma.
    Shooshtarizadeh T; Nazeri A; Zare-Mirzaie A; Movahedinia S
    Pathol Res Pract; 2016 Apr; 212(4):335-9. PubMed ID: 26948096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative SPECT/CT for differentiating between enchondroma and grade I chondrosarcoma.
    Choi WH; Han EJ; Chang KB; Joo MW
    Sci Rep; 2020 Jun; 10(1):10587. PubMed ID: 32601314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chondrosarcoma: A Diagnostic Imager's Guide to Decision Making and Patient Management.
    Logie CI; Walker EA; Forsberg JA; Potter BK; Murphey MD
    Semin Musculoskelet Radiol; 2013 Apr; 17(2):101-15. PubMed ID: 23673542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
    Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
    Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidental long bone cartilage lesions: is any further imaging workup needed?
    Ahmed S; Jubouri S; Mulligan M
    Skeletal Radiol; 2021 Jun; 50(6):1189-1196. PubMed ID: 33169221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadd45β expression in chondrosarcoma: a pilot study for diagnostic and biological implications in histological grading.
    Zenmyo M; Tanimoto A; Sakakima H; Yokouchi M; Nagano S; Yamamoto T; Ishido Y; Komiya S; Ijiri K
    Diagn Pathol; 2010 Oct; 5():69. PubMed ID: 20942912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
    Takeuchi A; Yamamoto Y; Tsuneyama K; Cheng C; Yonekura H; Watanabe T; Shimizu K; Tomita K; Yamamoto H; Tsuchiya H
    Cancer; 2007 Jun; 109(12):2532-40. PubMed ID: 17497647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.
    Matsuura S; Oda Y; Matono H; Izumi T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2010 Mar; 41(3):343-51. PubMed ID: 19896699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.